Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Revenue: | ||||
| Total revenue | $ 11,461 | $ 5,792 | $ 31,759 | $ 14,849 |
| Cost of products sold and services: | ||||
| Total cost of products sold and services | 10,169 | 5,606 | 29,048 | 14,170 |
| Operating expense: | ||||
| Pharmacy operations | 4,392 | 3,750 | 11,970 | 9,428 |
| General and administrative | 6,087 | 5,320 | 18,729 | 16,733 |
| Selling and marketing | 2,126 | 1,909 | 6,738 | 5,056 |
| Research and development | 178 | 232 | 952 | 601 |
| Total operating expense | 12,783 | 11,211 | 38,389 | 31,818 |
| Operating loss | (11,491) | (11,025) | (35,678) | (31,139) |
| Other gain (loss), net | 0 | 7 | 0 | 206 |
| Interest income | 0 | 7 | 1 | 74 |
| Interest expense | (315) | (260) | (845) | (328) |
| Loss before income taxes | (11,806) | (11,271) | (36,522) | (31,187) |
| Income tax expense | 0 | (2) | (24) | (2) |
| Net loss | (11,806) | (11,273) | (36,546) | (31,189) |
| Comprehensive loss | $ (11,806) | $ (11,273) | $ (36,546) | $ (31,189) |
| Net loss per share - basic (in USD per share) | $ (0.15) | $ (0.34) | $ (0.60) | $ (0.96) |
| Net loss per share - diluted (in USD per share) | $ (0.15) | $ (0.34) | $ (0.60) | $ (0.96) |
| Weighted average shares outstanding - basic (in shares) | 80,045,995 | 32,750,831 | 60,947,511 | 32,580,199 |
| Weighted average shares outstanding - diluted (in shares) | 80,045,995 | 32,750,831 | 60,947,511 | 32,580,199 |
| Pharmacy and hardware revenue | ||||
| Revenue: | ||||
| Total revenue | $ 11,266 | $ 5,659 | $ 31,210 | $ 14,165 |
| Cost of products sold and services: | ||||
| Total cost of products sold and services | 10,113 | 5,539 | 28,827 | 13,744 |
| Service revenue | ||||
| Revenue: | ||||
| Total revenue | 195 | 133 | 549 | 684 |
| Cost of products sold and services: | ||||
| Total cost of products sold and services | $ 56 | $ 67 | $ 221 | $ 426 |
| X | ||||||||||
- Definition Pharmacy Operations Expense No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|